
Lima hospitals warn of high flu activity
Feb. 5—LIMA — Lima doctors are asking the public to take precautionary measures as emergency departments and urgent cares report record patient volumes for flu and other respiratory illnesses.
Allen County Health Commissioner Brandon Fischer said roughly 60 Allen County residents were hospitalized with influenza in January. Another 30 have been hospitalized with flu-related illness five days into February, Fischer said during a press conference Wednesday.
"We're on track to surpass (January levels) by the time next week hits," Fischer said.
Mercy Health-St. Rita's Medical Center, Lima Memorial Health System, Allen County Public Health and the Auglaize and Putnam County health departments issued a joint warning Wednesday asking residents to take preventative measures and seek the appropriate level of care so health care facilities are not overwhelmed.
Already, health officials say the uptick in flu activity means patients may experience longer than usual wait times at the emergency department, urgent care or primary care.
"As we are seeing exceptionally high cases of Influenza A and other respiratory illnesses, it's crucial for residents to take flu symptoms seriously and seek care at the appropriate level so we are able to continue delivering the right level of care at the right time, without overloading our systems," said Dr. Matthew Owens, chief clinical officer for Mercy Health-Lima, said in a news release.
"While we are experiencing record numbers of patients across our emergency departments, urgent cares and primary care offices, we remain committed to providing the absolute best care for our community," Owens said. "We appreciate your patience as you may experience longer than usual wait times during peak season."
Health officials say residents who suspect they may have the flu or another respiratory illness should stay home, avoid visiting loved ones in the hospital or long-term care facilities and consider wearing a mask indoors to prevent others from becoming sick.
Residents should get their annual flu vaccine and wash their hands regularly as well, they said.
Allen County Public Health's wastewater surveillance system, an early detection measure intended to warn hospitals and other facilities of potential outbreaks, detected a 500% increase in influenza last week, Fischer said Wednesday.
Lima hospitals reported an increase in emergency department and urgent care visits two days later, he said.
Mild flu symptoms such as fever, cough, congestion and body aches can be treated by a primary care doctor, urgent care or telehealth provider, health officials said. Anyone exhibiting serious signs of illness such as trouble breathing, chest pain, confusion or high fever who does not respond to medication should seek immediate help from an emergency department.
Health officials say high-risk patients such as young children, older adults, pregnant women and anyone with underlying health conditions should consult with their doctor at the first sign of illness.
"By working together, we can reduce the strain on emergency services and ensure that everyone receives timely and effective treatment," said Dr. Susan Kaufman, vice president and chief medical officer of Lima Memorial Health System, in the release.
She added, "With a significant increase in patients, our health-care teams are working tirelessly to meet the growing demand. We encourage the community to seek the appropriate level of care to help us manage resources effectively and continue providing high-quality care for all."
Featured Local Savings
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Towering over Jerusalem: Shaare Zedek to double its capacity with new expansion
Shaare Zedek Medical Center gets permission to double its capacity with a new facility and integration with Kfar Shaul Mental Health Center. The competition for patients and prestige between Hadassah-University Medical Centers and Shaare Zedek Medical Center has been an ongoing rivalry for decades. But the race is no longer really necessary, as both medical facilities are brimming with patients as the surrounding population grows. To meet the burgeoning health demands, the government has decided to expand the existing medical centers and dismissed plans to construct any new general hospitals in the capital. To that end, Shaare Zedek has received permission from the state to double its capacity, with a 20-story tower to be built over its existing outdoor parking lot; Hadassah Medical Center in Ein Kerem has been busily refurbishing its original round building. On its two campuses, Ein Kerem and Mount Scopus, Hadassah's medical centers have more than 1,300 beds, 31 operating rooms, and nine special intensive care units, in addition to the five schools for medical professions. Shaare Zedek is the largest multidisciplinary medical center in the city, offering advanced services in a wide array of specialties, treating over a million patients annually in its 30 inpatient departments and 70 outpatient clinics and units. Its obstetrics department delivers 21,000 babies annually, making it the busiest in the world. 'You can't fit a pin in all the hospitals,' said Prof. Jonathan Halevy, Shaare Zedek's president, implying that these medical institutions are running at full capacity. 'The new building will cover 120,000 square meters and will cost about NIS 2.5 billion,' added Halevy, who served as Shaare Zedek's director-general from 1988, when there were 300 beds, to over 1,000 in 2019. 'We are working hard to raise money from donations, but the government has committed itself to match funds, perhaps close to 50% of what we raise.' In addition, it was decided that Shaare Zedek would integrate the Kfar Shaul Mental Health Center into its facilities. The public psychiatric hospital was established in 1951 between the Givat Shaul and Har Nof neighborhoods, on the grounds of the former Deir Yassin Arab village. Kfar Shaul could have been taken over by the nearby Herzog Medical Center, a psychiatric, chronic care, and rehabilitation facility. Dr. Ya'alov Haviv, director-general of Herzog, commented that he would have been happy to have incorporated Kfar Shaul into his medical institution. However, the government now has a policy of integrating psychiatric institutions with general hospitals. THE SHAARE ZEDEK tower, which will not obstruct Bayit Vagan residents' view, will be built in two phases. The first will open in about six and a half years, with the lowest nine stories functional. The facade of the whole tower will be built, and the 11 upper floors will function several years later. A helicopter pad on the roof will receive emergency patients. Halevy noted that the current departments, which already offer all medical services, will be expanded and upgraded with the new tower. 'We will have an entirely new emergency department with all the newest equipment. We expect we will deliver 30,000 babies a year when the building is complete,' he predicted. 'Shaare Zedek will be one of the three largest medical centers in Israel – quite a long way for the 20-bed hospital that opened at the western entrance to the city in 1902.' Although there is currently a significant shortage of physicians and nurses in Israel, Halevy said they will be replaced as new physicians will graduate and specialize. The decision to allow colleges, and not just universities, to open nursing schools will also increase the pool of nurses. Halevy is in a position to know: He was the chairman of the team of the Planning and Budgeting Committee of the Council for Higher Education, which examined the readiness of three new medical schools: Reichman University, the Weizmann Institute of Science, and the University of Haifa. THE GOVERNMENT'S decision to approve the tower was announced, appropriately, on Jerusalem Day by Health Minister Uriel Busso and Jerusalem Affairs and Jerusalem Affairs Minister Meir Porush. They said the step is being taken 'to strengthen the hospitalization system and ensure that physical and mental treatment will be provided at the same hospital.' The decision is a 'major milestone in the development of the medical center, which is a central medical anchor for Jerusalem and the entire central region,' Shaare Zedek director-general Prof. Ofer Merin told In Jerusalem. 'The doubling of capacity will significantly improve the quality of treatment and provide advanced and humane medicine to hundreds of thousands of additional patients from Jerusalem and all over the country. 'Physical and psychological health are linked. One affects the other. Today, we have only ambulatory psychiatry care, but with the new tower we will have inpatient beds as well,' he said. 'The population of Jerusalem is expected to double by 2045, so if medical centers in the capital don't expand, many patients will not be treated. We thought of building the tower about five years ago. People live longer, and that means they need more medical treatment. We also perform surgery and other treatments on people in their 90s that [we] were fearful of doing before.' Bosso said that the tower will serve 'as a lever to improve medical services for the city's residents and strengthen the health infrastructure in the capital.' Porush added: 'This significant decision reflects the strategic importance of Jerusalem in the areas of health and services for residents. It is very good news for the millions of residents of greater Jerusalem; it will improve the quality of life here and deepen health equity in Israel.' Sign up for the Health & Wellness newsletter >>


Business Upturn
3 days ago
- Business Upturn
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) — LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX Diagnostics Chris Hole [email protected] Scius Communications Katja Stout+44 778 943 5990 [email protected]
Yahoo
3 days ago
- Yahoo
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX DiagnosticsChris Holeenquires@ Scius CommunicationsKatja Stout+44 778 943 5990katja@ Daniel Gooch+44 774 787 5479daniel@ _____________________1 This LEX Diagnostics product is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. It is not available for sale or distribution in the U.S., the U.K. or any other jurisdiction. All product descriptions, data, or discussions are preliminary, subject to change, and do not represent final or FDA-approved claims, indications, or labeling.